Option chain shows key data for Assembly Biosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) Stock, Option Chain

Assembly Biosciences

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

Equities

News

Health Care

General

ASMB

Assembly Biosciences reported interim results from its Phase 1a study of ABI-5366, a long-acting HSV inhibitor for recurrent genital herpes. The drug showed a favorable safety profile and achieved target plasma concentrations for antiviral efficacy.

Assembly Biosciences&#39; Investigational Herpes Treatment Shows Safety In Healthy Participants (UPDATED)

Coins,Money,Increase,To,Profit,For,Concept,Investment,Fund,Finance

Long Ideas

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

AMSWA

TTSH

Insiders Buying American Software And 2 Other Stocks

Penny Stocks

Small Cap

Movers

ACHV

ATXI

BLBD

BRSH

CMND

CNTB

HCDI

HPCO

HRYU

ICVX

INAB

IONM

KAVL

ONTX

ORCL

SVMH

TENX

WULF

XCUR

Shares of  Icosavax, Inc.  (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion.

Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences Inc

Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Neutral and maintains $14 price target.

Price Target

Reiteration

Analyst Ratings

NTLA

Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $14 Price Target

Barclays analyst Simon Coles maintains Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) with a Overweight and raises the price target from $215 to $240.

Barclays Maintains Overweight on Taiwan Semiconductor, Raises Price Target to $240

BMO Capital analyst Kelly Bania maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Outperform and raises the price target from $980 to $1075.

COST

BMO Capital Maintains Outperform on Costco Wholesale, Raises Price Target to $1075

PLAG

Planet Green Holdings Shares Halted To The Downside; Stock Now Down -4.42%

Wedbush analyst Nick Setyan maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Outperform and lowers the price target from $60 to $50.

JACK

Wedbush Maintains Outperform on Jack In The Box, Lowers Price Target to $50

BMO Capital analyst Kelly Bania maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Outperform and raises the price target from $80 to $100.

BMO Capital Maintains Outperform on Walmart, Raises Price Target to $100

BBIO

BridgeBio Pharma Says The Continued Curve Separation Of The Composite Endpoint Of ACM And Recurrent Cardiovascular-Related Hospitalizations Emphasizes The Importance Of Early Intervention Resulting In Early And Sustained Clinical Benefits, With Acoramidis Demonstrating 46% And 48% Reductions In The Composite Endpoint Of ACM And Recurrent CVH At Months 36 And 42, Respectively

- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone at Month 36 within the Open Label Extension
- The continued curve separation of the composite endpoint of ACM and recurrent cardiovascular-related hospitalizations (CVH) emphasizes the importance of early intervention resulting in early and sustained clinical benefits, with acoramidis demonstrating 46% (p&lt;0.0001) and 48% (p&lt;0.0001) reductions in the composite endpoint of ACM and recurrent CVH at Months 36 and 42, respectively
- The preliminary results from this ongoing OLE study were also <a href="https://www.globenewswire.com/Tracker?data=nVrCQc_8jzuW0us-lfgFaR1qVTq_ZKK094j0nAXwGOzjpiNvmiPryHA11xPFHhBaYgKeFEBHeF4VNpSc_nsfEV21llyp7gkCWZiQNzvNSBAxj8g76mpygGVWg7b6bJ3rrNNv9OwALUuytnCVMDnjfDM4znS65x927SjyqqRsPQ4YxLUlnW0b98_MjiwYp5E1">simultaneously published in&nbsp;Circulation</a>
- A New Drug Application for acoramidis for the treatment of ATTR-CM is currently under review with the FDA, with a PDUFA action date of November 29, 2024
PALO ALTO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) ("BridgeBio" or the "Company"), a&nbsp;new type of biopharmaceutical company focused on genetic diseases, presented positive initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the American Heart Association (AHA) Scientific Sessions. ATTRibute-CM was designed to evaluate the efficacy and safety of acoramidis, an investigational, near-complete, orally-administered, small molecule stabilizer of TTR. The preliminary results from this ongoing OLE study were also <a href="https://www.globenewswire.com/Tracker?data=nVrCQc_8jzuW0us-lfgFaR1qVTq_ZKK094j0nAXwGOzjpiNvmiPryHA11xPFHhBaeIlDqZKG7OqhCoe56sd754bjgDVGcOiJ2s8HyuUyG7NflQCmEEQ3lIVaCQMHailwHLZaiAioFHGbJQ3YCr7zBvPyWKH7hTdh2uwLa8ooRVkFlNr8o40ZFfvRncYmj6k3">simultaneously published in&nbsp;Circulation</a>. The OLE study involves 330 participants who completed the 30-month ATTRibute-CM Phase 3 study.

BridgeBio Pharma Presented Initial Outcomes From The ATTRibute-CM Open-label Extension Study Of Acoramidis In ATTR-CM At The AHA Scientific Sessions; Acoramidis Demonstrated The Earliest Known Time To Separation In Cardiovascular Outcomes In The  ATTRibute-CM Study (3 Months), With Statistically Significant Risk Reduction Of 36% On All-Cause Mortality Alone At Month 36 Within The Open Label Extension

BMO Capital analyst James Thalacker maintains Entergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) with a Outperform and lowers the price target from $166 to $159.

BMO Capital Maintains Outperform on Entergy, Lowers Price Target to $159

Benchmark analyst Nathan Martin reiterates Arch Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCH#NYSE">ARCH</a>) with a Buy and maintains $180 price target.

ARCH

Benchmark Reiterates Buy on Arch Resources, Maintains $180 Price Target

Many Senate Republicans want the House Ethics Committee report on Matt Gaetz to be released. Gaetz is a close ally of President-elect Donald Trump.
<a href="https://www.cnbc.com/2024/11/18/trump-ag-matt-gaetz-house-ethics-panel-report-meeting.html" title="https://www.cnbc.com/2024/11/18/trump-ag-matt-gaetz-house-ethics-panel-report-meeting.html">https://www.cnbc.com/2024/11/18/trump-ag-matt-gaetz-house-ethics-panel-report-meeting.html</a> &nbsp;

Politics

'House Ethics panel to meet on Trump attorney general pick Matt Gaetz report Wednesday' - CNBC

Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) promises discounts and exclusive offers <a href="https://www.benzinga.com/topic/holidays">this holiday shopping season</a>. 
The retailer aims to offer an enhanced shopping experience, both online and in stores, with early access for Walmart+ members.
Starting at noon ET on Nov. 25, Walmart+ members will get a head start on Black Friday deals before the general public at 5 p.m. ET. Walmart&#8217;s holiday sales will feature steep discounts across top categories like electronics, toys, and fashion, with doorbuster deals available in-store from 6 a.m. local time on Black Friday.
Walmart promises savings across brands like Reebok, Michael Kors, and Dyson. Highlighted deals include: 
<ul>
<li>Dyson V11 Extra Cordless Vacuum Cleaner for $349.99, saving shoppers $250 off the regular price. </li>
<li>A TCL 65-inch 4K UHD Smart TV for $228, a discount of $301.</li>
<li>A Restored Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) MacBook Air bundle priced at $194, saving $81.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/news/earnings/24/11/42031958/niu-q3-earnings-scooter-volume-up-but-price-drops-and-margins-tighten-strong-q4-outlook-and-more" target="_blank" rel="noreferrer noopener">Niu Q3 Earnings: Scooter Volume Up, But Price Drops And Margins Tighten, Strong Q4 Outlook And More</a>
Sign-ups are available for a discounted annual fee of $49 until Dec. 2. This membership perk provides early shopping windows for Black Friday and Cyber Monday events and other exclusive offers throughout the holiday season.
Walmart&#8217;s Cyber Monday deals will start on Sunday, Dec. 1, at 5 p.m. ET for Walmart+ members and at 8 p.m. ET for all customers. 
Featured deals include: 
<ul>
<li>The $898 Sony Group Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) 75-inch BRAVIA 4K HDR LED TV, a savings of $600.</li>
<li>The $98 Ninja Grand Kitchen System and the $48.98 LEGO Star Wars Darth Vader Helmet.</li>
</ul>
Walmart has enhanced its holiday shopping features, offering customers a personalized search experience, expanded delivery options, and the ability to schedule delivery for large items. 
This year, Walmart also partnered with Angi for convenient installation services, including home décor and TV setups, catering to various holiday needs.
Amazon.Com Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) U.S. sales on Cyber Monday reached <a href="https://www.benzinga.com/news/24/10/41185124/amazon-to-boost-workforce-by-250k-for-2024-holidays-joining-retail-hiring-surge">$12.4 billion in 2023</a>, rising 9.6% and surpassing the $12 billion forecast. Total online sales for Cyber Week hit $38 billion, exceeding the $37.2 billion estimate.
Bank of America analyst Robert Ohmes predicted strong third-quarter results.
Ohmes expects Walmart&#8217;s third-quarter earnings per share to reach $0.52, driven by grocery and <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41913981/what-to-expect-from-walmarts-q3-earnings" rel="noreferrer noopener">health/wellness sales growth</a>. Walmart&#8217;s store remodels, online product expansion, and express delivery upgrades boost sales and customer loyalty. Despite a shorter holiday season, Walmart&#8217;s strong digital and omni-channel offerings could see increased online sales.
Walmart faces risks from Trump&#8217;s tariff plans, which may raise costs and challenge its low-price strategy.
Tax cuts enable Walmart to reinvest in technology, strengthening its edge against rivals like Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>).
Investors can gain exposure to Walmart through SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>).
Price Action: WMT stock is up 0.53% at $84.70 premarket at last check Monday. Walmart stock surged 59% year-to-date.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/41978712/asml-projects-revenue-surge-to-63-billion-by-2030-eyes-ai-and-chip-market-boom" target="_blank" rel="noreferrer noopener">ASML Projects Revenue Surge to $63 Billion by 2030, Eyes AI and Chip Market Boom</a></li>
</ul>

AAPL

AMZN

Sony Group Corporation American Depositary Shares

SONY

Walmart Gears Up For Black Friday, Cyber Monday Specials: Major Discounts On Apple MacBooks, Sony TVs

Deep-pocketed investors have adopted a bullish approach towards Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HIMS usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 28 extraordinary options activities for Hims &amp; Hers Health. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 71% leaning bullish and 14% bearish. Among these notable options, 12 are puts, totaling $960,282, and 16 are calls, amounting to $827,190.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $15.0 and $42.0 for Hims &amp; Hers Health, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Hims &amp; Hers Health's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Hims &amp; Hers Health's whale activity within a strike price range from $15.0 to $42.0 in the last 30 days. 
<h3>Hims &amp; Hers Health Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731946560_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$5.4</td>
<td>$5.3</td>
<td>$5.3</td>
<td>$25.00</td>
<td>$208.8K</td>
<td>3.5K</td>
<td>1.7K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/29/24</td>
<td>$1.5</td>
<td>$1.4</td>
<td>$1.44</td>
<td>$20.50</td>
<td>$147.0K</td>
<td>2.0K</td>
<td>2.3K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.35</td>
<td>$1.25</td>
<td>$1.34</td>
<td>$28.00</td>
<td>$132.7K</td>
<td>2.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.45</td>
<td>$2.4</td>
<td>$2.4</td>
<td>$20.00</td>
<td>$120.0K</td>
<td>6.2K</td>
<td>989</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$2.5</td>
<td>$2.4</td>
<td>$2.45</td>
<td>$21.00</td>
<td>$113.9K</td>
<td>5.2K</td>
<td>480</td>
</tr>
</tbody>
</table>

<h3>About Hims &amp; Hers Health</h3>
Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
In light of the recent options history for Hims &amp; Hers Health, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Hims &amp; Hers Health</h3>
<ul>
<li>Currently trading with a volume of 10,964,198, the HIMS's price is up by 12.73%, now at $21.78. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 98 days.</li>
</ul>
<h3>What Analysts Are Saying About Hims &amp; Hers Health</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $23.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from B of A Securities downgraded its rating to Underperform, setting a price target of $18. 
&#x2A; Reflecting concerns, an analyst from Piper Sandler lowers its rating to Neutral with a new price target of $21. 
&#x2A; An analyst from Canaccord Genuity persists with their Buy rating on Hims &amp; Hers Health, maintaining a target price of $28. 
&#x2A; An analyst from Deutsche Bank has decided to maintain their Hold rating on Hims &amp; Hers Health, which currently sits at a price target of $27. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Hims &amp; Hers Health with a target price of $25. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Hims &amp; Hers Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Unpacking the Latest Options Trading Trends in Hims & Hers Health

<a href="https://www.benzinga.com/24/11/41947081/kevin-oleary-says-great-entrepreneurs-and-great-leaders-want-to-get-up-in-the-morning-and-get-to-work-heres-what-he-says-drives-them">Kevin O&#8217;Leary</a> recently appeared on The Daniela Cambone Show, where he discussed the current state of the U.S. energy sector and broader market trends. O&#8217;Leary, known for his outspoken views on business and investment, shared his thoughts on how regulatory changes under the Biden-Harris administration have impacted the economy, particularly in energy and how markets are reacting now.
Don't Miss:
<ul>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai-2">Be an early investor with just $1,000 for only $0.50/share today before the offer closes in the next few days</a>!</li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">You can still get 4,000 of its pre-IPO shares for with $1,000 for just $0.25/share</a></li>
</ul>
O&#8217;Leary made it clear that a lot of the recent market movement is due to what he sees as the lifting of &#8220;a trillion dollars worth of regulatory pressure.&#8221; Reflecting on the <a href="https://www.benzinga.com/personal-finance/24/11/42013651/is-trumps-second-term-going-to-affect-student-loan-borrowers-here-are-3-potential-changes">Trump administration</a>, he explained how previous deregulation policies benefited multiple industries, especially energy.&nbsp;
"Trump stripped away a lot of the regulation and energy was a huge beneficiary," O&#8217;Leary said. According to him, this helped energy companies thrive, creating a more open environment for growth and expansion.
However, O&#8217;Leary also pointed out how the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41976407/ben-horowitz-the-biden-regulators-lied-about-crypto">Biden administration&#8217;s policies</a> reversed some of that. He specifically mentioned how regulations were added to the energy sector, which, in his view, made things harder.&nbsp;
Trending: This rooftop wind turbine is taking on a market projected to reach over $900 billion by 2032 —<a href="https://www.benzinga.com/money/halcium"> With already over 40,000 users signing up to purchase, here's a chance to be an early investor today!</a>
"Biden-Harris, whether you liked them or not, added a lot of layers of administration and regulation," he said. He noted that natural gas exports were halted and new energy permits became harder to obtain. According to O&#8217;Leary, these measures had a cooling effect on the energy sector. "They made it difficult for companies to expand or even get new projects started," he added.
Despite these setbacks, O&#8217;Leary believes the market mood is improving. &#8220;The market's celebrating a more positive view of expansion,&#8221; he said. This shift is partly due to the hope that the regulatory environment might become more business-friendly. With the lifting of certain restrictions, O'Leary believes energy companies and other sectors are seeing more growth opportunities again.
O&#8217;Leary also discussed other sectors benefiting from changes in the regulatory landscape, including the <a href="https://www.benzinga.com/media/24/11/42022531/cathie-wood-backs-elon-musks-2-trillion-doge-initiative-says-tesla-ceos-access-to-proprietary-data-and-ai-gives-him-an-edge">cryptocurrency market</a>. In particular, he commented on the recent rumors surrounding the Commodity Futures Trading Commission (CFTC) potentially taking over crypto regulation from the Securities and Exchange Commission (SEC).&nbsp;
See Also: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
O&#8217;Leary remarked that the SEC's litigious approach to regulation may have hindered growth in the digital currency space and that fewer regulations would have been positive.
O&#8217;Leary also shared his optimism about technology and finance, particularly digital payments. "I'm a big believer in digital payment systems beyond just tokens and Bitcoin," he said. He sees these systems as essential for the future of global finance, offering potential far beyond what we currently see in the world of cryptocurrencies.
In a final reflection, O&#8217;Leary noted that democracy has a way of correcting itself. "When things get too crazy, to the left, to the right, it somehow figures out how to fix itself," he said.&nbsp;
Read Next:
<ul>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before it closes in a few days.</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>

Startups

Kevin O'Leary: 'Biden-Harris Regulations Held Back Energy, But Markets Now Celebrate Expansion'

Deep-pocketed investors have adopted a bullish approach towards Goldman Sachs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GS usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Goldman Sachs Gr. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 40% leaning bullish and 40% bearish. Among these notable options, 2 are puts, totaling $70,260, and 8 are calls, amounting to $477,053.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $300.0 and $620.0 for Goldman Sachs Gr, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Goldman Sachs Gr's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Goldman Sachs Gr's whale trades within a strike price range from $300.0 to $620.0 in the last 30 days. 
<h3>Goldman Sachs Gr Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731946555_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$30.2</td>
<td>$30.15</td>
<td>$30.2</td>
<td>$590.00</td>
<td>$141.9K</td>
<td>74</td>
<td align="right">51</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$171.15</td>
<td>$171.05</td>
<td>$171.0</td>
<td>$430.00</td>
<td>$68.4K</td>
<td>1.1K</td>
<td align="right">47</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$293.0</td>
<td>$292.3</td>
<td>$293.0</td>
<td>$300.00</td>
<td>$58.6K</td>
<td>74</td>
<td align="right">2</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$171.3</td>
<td>$169.55</td>
<td>$169.91</td>
<td>$430.00</td>
<td>$50.9K</td>
<td>1.1K</td>
<td align="right">27</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$171.3</td>
<td>$169.3</td>
<td>$169.91</td>
<td>$430.00</td>
<td>$50.9K</td>
<td>1.1K</td>
<td align="right">24</td>
</tr>
</tbody>
</table>

<h3>About Goldman Sachs Gr</h3>
Goldman Sachs is a leading global investment banking and asset management firm. Approximately 20% of its revenue comes from investment banking, 45% from trading, 20% from asset management and 15% from wealth management and retail financial services. Around 60% of the company's net revenue is generated in the Americas, 15% in Asia, and 25% in Europe, the Middle East, and Africa.
In light of the recent options history for Goldman Sachs Gr, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Goldman Sachs Gr Standing Right Now?</h3>
<ul>
<li>With a trading volume of 414,407, the price of GS is down by -0.52%, reaching $590.47.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 58 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Goldman Sachs Gr</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $670.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Goldman Sachs Gr, maintaining a target price of $661. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Goldman Sachs Gr, which currently sits at a price target of $680. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Goldman Sachs Gr, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Looking At Goldman Sachs Gr's Recent Unusual Options Activity

Whales with a lot of money to spend have taken a noticeably bullish stance on Salesforce.
Looking at options history for Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) we detected 38 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 44% with bearish.
From the overall spotted trades, 15 are puts, for a total amount of $976,938 and 23, calls, for a total amount of $1,067,057.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $200.0 to $340.0 for Salesforce over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Salesforce's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Salesforce's whale trades within a strike price range from $200.0 to $340.0 in the last 30 days. 
<h3>Salesforce Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731946550_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$7.7</td>
<td>$6.9</td>
<td>$7.7</td>
<td>$330.00</td>
<td>$291.0K</td>
<td>511</td>
<td align="right">514</td>
</tr>
<tr>
<td>CRM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$7.8</td>
<td>$7.75</td>
<td>$7.8</td>
<td>$330.00</td>
<td>$87.3K</td>
<td>511</td>
<td align="right">120</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$16.95</td>
<td>$16.75</td>
<td>$16.75</td>
<td>$330.00</td>
<td>$83.7K</td>
<td>1.4K</td>
<td align="right">70</td>
</tr>
<tr>
<td>CRM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$28.55</td>
<td>$28.2</td>
<td>$28.2</td>
<td>$340.00</td>
<td>$76.1K</td>
<td>57</td>
<td align="right">30</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$107.3</td>
<td>$105.5</td>
<td>$107.17</td>
<td>$220.00</td>
<td>$74.9K</td>
<td>1.0K</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Salesforce</h3>
Salesforce provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Following our analysis of the options activities associated with Salesforce, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Salesforce</h3>
<ul>
<li>With a volume of 1,091,100, the price of CRM is down -0.47% at $323.72. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 15 days.</li>
</ul>
<h3>What The Experts Say On Salesforce</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $369.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Salesforce, which currently sits at a price target of $330. 
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on Salesforce, which currently sits at a price target of $385. 
&#x2A; An analyst from Loop Capital has decided to maintain their Hold rating on Salesforce, which currently sits at a price target of $340. 
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Buy rating for Salesforce, targeting a price of $400. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Salesforce with a target price of $390. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Salesforce options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

A Closer Look at Salesforce's Options Market Dynamics

WIIM

AILE

iLearningEngines shares are trading lower after the company announced a cybersecurity incident that will have a material impact on its operations during its Q4. Also, the SEC issued a subpoena for various documents and information.

NBA legend <a href="https://www.benzinga.com/topic/isiah-thomas">Isiah Thomas</a>&#8216; hemp company One World Products Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OWPC#OTC">OWPC</a>) is celebrating its first royalty payment.
Over the years, OWP has formed alliances with industry operators such as Stellantis, Flex-N-Gate, Orbis, and West Michigan Compounding to integrate green practices into mainstream markets, especially the automotive industry.
&#8220;Our strategic partnerships with industry giants such as Stellantis, Flex-N-Gate, Orbis, and West Michigan Compounding are pivotal as we drive forward the integration of green practices into mainstream markets," <a href="https://www.benzinga.com/markets/cannabis/24/10/41337721/nba-legends-eco-friendly-hemp-packaging-shakes-up-auto-industry-unveiled-at-detroit-showcase">said</a> Thomas, OWP chairman and CEO. "With their support, we are setting new benchmarks for what it means to operate responsibly within the automotive industry.&#8221;
The NBA hall of famer and sports legend-turned cannabis entrepreneur is also famous because for his mission to produce hemp cars.
&#8220;I envision a future where the Fords, the GMs, the Stellantis&#8217; of the world take plastics out of their automobiles and infuse them with industrial hemp to replace those plastics, thus reducing their carbon footprint,&#8221; Thomas told Benzinga&#8217;s <a href="https://www.benzinga.com/author/javier-hasse" target="_blank" rel="noreferrer noopener">Javier Hasse</a> in a<a href="https://www.benzinga.com/markets/cannabis/22/06/27820626/isiah-thomas-hemp-cars" target="_blank" rel="noreferrer noopener"> 2022 interview.</a>
Read Also: <a href="https://www.benzinga.com/markets/cannabis/23/03/31383033/isiah-thomas-from-nba-champ-to-business-mogul-hemp-cars-cbd-drinks-champagne-producer">Isiah Thomas: From NBA Champ To Business Mogul, Hemp Cars, CBD Drinks &amp; Champagne Producer</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
The global industrial hemp market is forecasted to reach $16.82 billion by 2030, expanding at a CAGR of 17.5% from 2024, according to the 2024 Grand View Research report. That said, OWP is capitalizing on the surge in hemp applications across various industries.
Meanwhile, OWP is advancing sustainable hemp-based packaging solutions in response to increasing demand for eco-friendly alternatives to single-use plastics.
The company, in collaboration with partners like Orbis and Flex-N-Gate, "offers viable, sustainable hemp-based packaging solutions that could dramatically reduce the ecological footprint of the packaging industry," OWP said in a press release.
Initially focused exclusively on Colombian cannabis operations, the company now embraces new opportunities as well, while the strategic shift ensures alignment with global sustainability goals and market demands.
Leveraging insights gained from Isiah Thomas&#8217;s extensive connections within the pro athlete community, OWP&#8217;s Pro-11 wellness line caters to the increasing consumer preference for eco-friendly and health-conscious options.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/03/37921288/legal-hurdles-dont-deter-isiah-thomas-hemp-empire-announces-new-collab-in-colombia">Legal Hurdles Don&#8217;t Deter Isiah Thomas&#8217; Hemp Empire, Announces New Collab In Colombia</a></li>
</ul>

Cannabis

OWPC

Isiah Thomas' One World Products Makes Strides In Sustainability With Strategic Hemp Innovations

BMO Capital analyst Simeon Siegel maintains Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) with a Market Perform and raises the price target from $55 to $60.

BMO Capital Maintains Market Perform on Tapestry, Raises Price Target to $60

<a href="https://techcrunch.com/2024/11/18/twenty-is-building-an-open-source-alternative-to-salesforce/#:~:text=While%20Twenty%20doesn't%20have,and%2020%2C000%20stars%20on%20GitHub.">https://techcrunch.com/2024/11/18/twenty-is-building-an-open-source-alternative-to-salesforce/#:~:text=While%20Twenty%20doesn't%20have,and%2020%2C000%20stars%20on%20GitHub.</a>
&nbsp;
If a software product is successful enough, you'll probably be able to find a company building an open source alternative. And yet, nobody has created a modern open source CRM product that can be considered as a serious competitor to Salesforce.
That's exactly what <a href="https://twenty.com/">Twenty</a> is trying to achieve. For the past couple of years, the startup has been iterating on a brand-new CRM platform and making everything available <a href="https://github.com/twentyhq/twenty?tab=License-1-ov-file#readme">on GitHub</a> under a permissive AGPLv3 license.
While Twenty doesn't have all the features that you can find in Salesforce, the company is slowly building a community of CRM and open source enthusiasts around it with more than 300 contributors in the last year and 20,000 stars on GitHub.
The startup's three co-founders worked together on a previous startup called Luckey that was acquired by Airbnb. It was a sort of mini CRM for Airbnb guests and hosts, specifically designed for vacation rentals.
When it was time to leave and start a new startup, they looked at the tech industry and noticed a trend. For the past few years, there has been a wave of open source startups replicating popular software-as-a-service products with a community-oriented approach. <a href="https://baserow.io/">Baserow</a> is trying to replicate Airtable. <a href="https://documenso.com/">Documenso</a> is working on a DocuSign alternative. <a href="https://formbricks.com/">Formbricks</a> has released a Qualtrics competitor. And the list goes on.
"And I realized that CRM is the biggest software market overall, because it covers marketing, customer support, operations —&nbsp;a CRM does everything," Twenty co-founder and CEO Félix Malfait told TechCrunch.
Arguably, some companies have already tried to build an open source CRM and take on Salesforce, such as SugarCRM. While SugarCRM has been quite successful, SugarCRM never reached the success of Salesforce or HubSpot. The company also stopped releasing its Community Edition in 2018.

'Twenty Is Building An Open Source Alternative To Salesforce' - TechCrunch

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Assembly Biosciences (ASMB – Research Report) today. The company's shares closed yester...

H.C. Wainwright Sticks to Their Hold Rating for Assembly Biosciences (ASMB)

Assembly Biosciences closes $12.6M in equity financings

In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Assembly Biosciences (ASMB – Research Report). The company's s...

H.C. Wainwright Sticks to Its Hold Rating for Assembly Biosciences (ASMB)

Assembly Biosciences GAAP EPS of -$1.98 beats by $0.25

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Assembly Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/asmb-stock-quote/">ASMB</a>) just reported results for the second quarter of 2024.<ul><li>Assembly Biosciences reported earnings per share of -$1.98. This was above the analyst estimate for EPS of -$2.23.</li><li>The company reported revenue of $8.53 million.</li><li>This was 43.17% better than the analyst estimate for revenue of $5.96 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/asmb-stock-earnings-assembly-biosciences-for-q2-of-2024/">ASMB Stock Earnings: Assembly Biosciences Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ASMB Stock Earnings: Assembly Biosciences Beats EPS, Beats Revenue for Q2 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Thermo Fisher (TMO – Research Report), Nyxoah (NYXH ...

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Nyxoah (NYXH) and Assembly Biosciences (ASMB)

Capitulation in biotech is near, as well as a rally – Piper Sandler

Assembly Biosciences GAAP EPS of -$1.51, revenue of $6.85M

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Assembly Biosciences (ASMB – Research Report) today. The company's shares closed last F...

H.C. Wainwright Keeps Their Hold Rating on Assembly Biosciences (ASMB)

CDNA

DTIL

EXEL

IBBQ

IDNA

NTRA

NYXH

PRAX

PTGX

SPRY

TRDA

Press Releases

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024

Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366

Assembly Biosciences Announces $12.6 Million in Equity Financings

Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

Earnings

Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366

Comments

Assembly Biosciences

Assembly Biosciences (ASMB) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga